The FDA has licensed the first pneumococcal vaccine for use in infants and toddlers. The 7-valent, polysaccharide-protein conjugate vaccine (Prevnar, Wyeth Lederle Vaccines, Philadelphia) was approved for active immunization of infants and toddlers against invasive disease (meningitis and bacteremia) caused by Streptococcus pneumoniae. The capsular serotypes contained in the conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) cause approximately 80% of invasive disease in children under age 6 years in the United States. The routine schedule is a four-dose series of 0.5 mL beginning at age 2 months.
Henney JE. Infant Pneumococcal Vaccine. JAMA. 2000;283(17):2228. doi:10.1001/jama.283.17.2228-JFD00003-2-1